For women that had surgical menopause, what value can Mira provide?Updated a month ago

For women in complete surgical menopause (bilateral oophorectomy), Mira can provide value primarily by monitoring longitudinal FSH trends and assessing physiologic response to estradiol therapy. This includes tracking symptom patterns, observing E3G trends as a proxy for estrogen exposure and absorption, and evaluating changes in FSH over time. Importantly, there are currently no universally accepted target ranges for FSH in the context of hormone therapy. Therefore, the clinical value of Mira lies not in achieving a specific FSH number, but in observing directionality and stability of trends. 

When interpreted alongside symptom response and E3G patterns, longitudinal FSH data can provide meaningful physiologic context to guide dose or route adjustments. In reproductive-aged women (ages 18–35), early follicular phase FSH levels (cycle days 2–5) are commonly observed below ~10–15 mIU/mL, broadly aligning with expected serum patterns. 

Elevated FSH has been associated with reproductive aging and, in observational research, linked to increased symptom burden and potential risk across bone, fracture, cardiovascular, and neurologic health domains. While it is reasonable to hypothesize that stabilization or reduction of elevated FSH may reflect a more favorable hormonal environment, the extent to which lowering FSH directly modifies long-term risk has not been definitively established. 

Although there are no established target FSH ranges in this setting, stabilization or reduction of elevated FSH — when interpreted alongside symptom improvement and E3G patterns — may provide supportive physiologic context when adjusting estradiol dose or delivery route.

You can find the full guide to using Mira in perimenopause and menopause here.